Denali Therapeutics (DNLI) Current Leases (2019 - 2025)

Denali Therapeutics (DNLI) has 7 years of Current Leases data on file, last reported at $9.2 million in Q3 2025.

• On a quarterly basis, Current Leases rose 14.04% year-over-year to $9.2 million in Q3 2025; TTM through Sep 2025 was $9.2 million, a 14.04% increase from a year earlier, with the FY2024 full-year figure at $8.3 million, up 14.44% from the prior year.
• Current Leases for Q3 2025 stood at $9.2 million, up from $8.9 million in the prior quarter.
• Over the last five years, Current Leases for DNLI reached as high as $9.2 million in Q3 2025 and fell as low as $4.9 million in Q1 2021.
• Historically, Current Leases has averaged $7.0 million across 5 years, with a median of $7.1 million in 2022.
• Across the five-year window, Current Leases jumped 34.58% in 2022 and declined 0.79% in 2023, its largest moves.
• Year by year, Current Leases stood at $5.5 million in 2021, then soared by 34.2% to $7.3 million in 2022, then fell by 0.79% to $7.3 million in 2023, then rose by 14.44% to $8.3 million in 2024, then increased by 10.3% to $9.2 million in 2025.
• Per Business Quant data, the three most recent Current Leases figures were $9.2 million in Q3 2025, $8.9 million in Q2 2025, and $8.6 million in Q1 2025.